115 related articles for article (PubMed ID: 3552712)
1. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.
Wirtz RA; Ballou WR; Schneider I; Chedid L; Gross MJ; Young JF; Hollingdale M; Diggs CL; Hockmeyer WT
Exp Parasitol; 1987 Apr; 63(2):166-72. PubMed ID: 3552712
[TBL] [Abstract][Full Text] [Related]
2. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen.
Richards RL; Hayre MD; Hockmeyer WT; Alving CR
Infect Immun; 1988 Mar; 56(3):682-6. PubMed ID: 3277918
[TBL] [Abstract][Full Text] [Related]
3. Plasmodium falciparum: elicitation by peptides and recombinant circumsporozoite proteins of circulating mouse antibodies inhibiting sporozoite invasion of hepatoma cells.
Hollingdale MR; Ballou WR; Aley SB; Young JF; Pancake S; Miller LH; Hockmeyer WT
Exp Parasitol; 1987 Jun; 63(3):345-51. PubMed ID: 2438152
[TBL] [Abstract][Full Text] [Related]
4. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.
Hoffman SL; Wistar R; Ballou WR; Hollingdale MR; Wirtz RA; Schneider I; Marwoto HA; Hockmeyer WT
N Engl J Med; 1986 Sep; 315(10):601-6. PubMed ID: 3526148
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum.
Russo DM; Sundy JS; Young JF; Maguire HC; Weidanz WP
J Immunol; 1989 Jul; 143(2):655-9. PubMed ID: 2472448
[TBL] [Abstract][Full Text] [Related]
8. Immune response of humans to the circumsporozoite protein of Plasmodium falciparum: limited T cell response to the immunodominant central repeat region.
Campbell JR; Paleologo FP; Franke ED; Ratiwayanto S; Hadiputranto H; Kurniawan L; Wistar R; Hoffman SL; Annis BA; Wasserman G
Am J Trop Med Hyg; 1988 Sep; 39(3):232-5. PubMed ID: 2459979
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antibody responses to the circumsporozoite protein repeat region and to intact sporozoites during acute falciparum malaria.
Brown AE; Webster HK; Pavanand K; Permpanich B; Sookto P; Sattabongkot J; Gingrich JB
Trans R Soc Trop Med Hyg; 1989; 83(2):154-7. PubMed ID: 2692219
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a hybrid Plasmodium falciparum malaria antigen.
Lockyer MJ; Cooper H; Tite J; Rowan W; Crowe JS
Parasitology; 1993 Jun; 106 ( Pt 5)():451-7. PubMed ID: 8341580
[TBL] [Abstract][Full Text] [Related]
11. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.
de Oliveira GA; Clavijo P; Nussenzweig RS; Nardin EH
Vaccine; 1994 Aug; 12(11):1012-7. PubMed ID: 7526570
[TBL] [Abstract][Full Text] [Related]
13. Effect of context and adjuvant on the immunogenicity of recombinant proteins and peptide conjugates derived from the polymorphic malarial surface antigen MSA2.
Jones GL; Spencer L; Lord R; Saul AJ
Vaccine; 1996 Jan; 14(1):77-84. PubMed ID: 8821653
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
15. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
16. Expression of Plasmodium falciparum circumsporozoite proteins in Escherichia coli for potential use in a human malaria vaccine.
Young JF; Hockmeyer WT; Gross M; Ballou WR; Wirtz RA; Trosper JH; Beaudoin RL; Hollingdale MR; Miller LH; Diggs CL
Science; 1985 May; 228(4702):958-62. PubMed ID: 2988125
[TBL] [Abstract][Full Text] [Related]
17. A multiple antigen peptide from the repetitive sequence of the Plasmodium malariae circumsporozoite protein induces a specific antibody response in mice of various H-2 haplotypes.
Del Giudice G; Tougne C; Louis JA; Lambert PH; Bianchi E; Bonelli F; Chiappinelli L; Pessi A
Eur J Immunol; 1990 Jul; 20(7):1619-22. PubMed ID: 2201549
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.
Richards RL; Swartz GM; Schultz C; Hayre MD; Ward GS; Ballou WR; Chulay JD; Hockmeyer WT; Berman SL; Alving CR
Vaccine; 1989 Dec; 7(6):506-12. PubMed ID: 2692333
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine.
Ballou WR; Hoffman SL; Sherwood JA; Hollingdale MR; Neva FA; Hockmeyer WT; Gordon DM; Schneider I; Wirtz RA; Young JF
Lancet; 1987 Jun; 1(8545):1277-81. PubMed ID: 2884410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
